Core Viewpoint - MDB Capital Holdings, LLC plans to host a Zoom webinar on March 31, 2025, to discuss its fourth quarter and full year 2024 results, with a press release to be issued prior to the call [1][2]. Company Overview - MDB Capital Holdings, LLC, founded in 1997, focuses on transforming deep technology ideas into valuable public companies through a unique public venture capital approach, primarily targeting pre-revenue, early-stage companies [3]. - The company operates under the MDB Capital brand, which includes a self-clearing broker-dealer and the PatentVest firm, specializing in intellectual property intelligence and consulting [4].

Core Insights - PatentVest released the "AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure" report, analyzing the evolving AI data center market and its implications for future infrastructure [1] - The enterprise data generation is expected to reach 1.2 million exabytes by 2025, necessitating advancements in digital infrastructure to support AI workloads [2] - The data center as a service market, valued at $71.92 billion in 2022, is projected to grow to $431.43 billion by 2030, driven by demand for AI-optimized infrastructure [3] Market Dynamics - AI-driven data centers are integrating AI-specific semiconductors, high-speed interconnects, liquid cooling, and renewable energy solutions to enhance efficiency and sustainability [3] - Intellectual property (IP) is crucial for unlocking the potential of evolving data centers, with companies expanding patent portfolios to secure foundational technologies [6] - The report highlights the competitive patent landscape, identifying key players and gaps in patent coverage that present opportunities for innovation [6] Competitive Landscape - The AI data center market is witnessing a surge in patent filings, with 77% of all filings originating from China, indicating its dominant role in shaping AI infrastructure [8] - Leading innovators include five top patent holders from China, one from South Korea, and others from the United States, showcasing a diverse competitive environment [8] - Patent disputes, such as Intel's $2.18 billion ruling and Netlist's $118 million lawsuit against Samsung, emphasize the strategic importance of IP in the sector [8]

Core Insights - The continuous glucose monitoring (CGM) market is rapidly evolving, driven by technological advancements and increasing demand for diabetes management solutions [1][3][5] Market Overview - The CGM market was valued at $11.63 billion in 2024 and is projected to reach $21 billion by 2029, indicating significant growth potential [3] - An estimated 537 million adults were affected by diabetes in 2021, with projections rising to 783 million by 2045, highlighting the urgent need for effective diabetes management tools [2] Key Players and Innovations - Major companies such as Dexcom, Abbott, Medtronic, and Roche are leading the way in advancing CGM technologies and solutions [5] - Innovations include non-invasive glucose monitoring and integration with mobile applications, enhancing convenience and accuracy for users [8] Market Dynamics - The emergence of over-the-counter (OTC) CGM products is expanding access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals [8] - A surge in patent filings indicates a competitive landscape where companies are actively protecting their innovations [8] Intellectual Property Strategy - The CGM market is characterized by ongoing litigation trends, reflecting the high stakes involved in securing leadership positions through intellectual property [8]

Core Insights - Invizyne Technologies, Inc. has been awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF) [1][2] - The project is part of the U.S. Department of Defense's BioMADE initiative, aimed at scaling up American biomanufactured products [2][3] - The global SAF market is projected to grow at a compound annual growth rate of 52.2%, reaching $27.4 billion by 2032 [5] Project Details - The BioMADE grant will facilitate the development of an enzyme production and processing pipeline for isobutanol, which can replace conventional petroleum-based fuels [6][4] - Invizyne's technology will be deployed in 100L pilot-scale facilities as part of this initiative [6] Broader Vision and Impact - Invizyne aims to establish a framework for expanding its cell-free approach into various industrial processes beyond biofuels [8] - The company believes its biomanufacturing platform, SimplePath™, will provide significant alternatives to traditional chemical production methods [11][10] - The initiative is expected to contribute to reducing greenhouse gas emissions and fostering a shift toward renewable solutions [8][7] Industry Context - BioMADE supports the scale-up of bioindustrial manufacturing technology, enhancing American competitiveness and securing the U.S. supply chain [9] - The initiative is part of a broader effort to build a diverse and competitive workforce in the bioindustrial manufacturing ecosystem [9]

Company Overview - Invizyne Technologies, Inc. specializes in cell-free, enzyme-based biomanufacturing systems aimed at producing commercially important molecules and chemicals for everyday life [6] - The company is headquartered in Monrovia, California, and is focused on redefining biomanufacturing through its SimplePath™ platform, which transforms natural or renewable resources into valuable biochemicals [6] Initial Public Offering (IPO) Details - Invizyne Technologies announced the closing of its IPO, offering 1,875,000 shares at a public offering price of $8.00 per share, resulting in gross proceeds of approximately $15,000,000 before expenses [1][2] - The shares began trading on NASDAQ under the ticker symbol "IZTC" on November 13, 2024 [1] - The company has granted a 45-day option to the underwriter to purchase up to 281,250 additional shares to cover over-allotments [2] Concurrent Private Placement - In a concurrent private placement, Invizyne issued 93,750 warrants at a purchase price of $0.125 per warrant, each warrant allowing the purchase of one share of common stock at an exercise price of $8.00 for five years [3] Regulatory Compliance - A registration statement on Form S-1 was filed with the SEC and declared effective on November 8, 2024, allowing the public offering to proceed [4]

Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced that its common shares will begin trading on the NASDAQ today, November 13, 2024 at approximately 12:00pm EST under the ticker symbol “IZTC.” About Invizyne Technologies, Inc.Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company head ...

Financial Performance - For the three months ended September 30, 2024, the net operating loss was $8,719,615, compared to a loss of $3,299,055 for the same period in 2023, indicating a significant increase in losses[8]. - The total operating income for the nine months ended September 30, 2024, was $1,013,816, a decrease of approximately 80% from $5,070,958 in the same period of 2023[8]. - The net loss attributable to MDB Capital Holdings, LLC for the nine months ended September 30, 2024, was $19,225,299, compared to $1,419,350 for the same period in 2023, showing a significant increase in net losses[8]. - For the nine months ended September 30, 2024, the net loss was $20,855,682, compared to a net loss of $1,760,981 for the same period in 2023, indicating a significant increase in losses[11]. - The company reported a net loss per Class A common share of $(2.07) for the nine months ended September 30, 2024, compared to $(0.24) for the same period in 2023, reflecting a worsening loss per share[8]. - The net operating loss for Q3 2024 was $(8,719,615), compared to a net operating loss of $(7,735,433) in Q3 2023, reflecting a deterioration in performance[88]. - The company reported a net loss of $8,440,490 for the three months ended September 30, 2024, compared to a net loss of $3,186,314 in the same period of 2023, reflecting a 164.9% increase in losses[157]. Operating Costs - Total operating costs for the nine months ended September 30, 2024, were $22,805,340, compared to $6,996,275 for the same period in 2023, indicating a significant increase in operating expenses[8]. - Total operating costs for Q3 2024 were $8,105,370, with general and administrative costs accounting for $5,170,772, which is a significant portion of total expenses[88]. - Compensation costs for the nine months ended September 30, 2024, reached $15,188,205, highlighting the significant expense in this area[89]. - Total general and administrative costs increased by 43.5% to $1,813,972 for the three-month period ended September 30, 2024, compared to $1,263,844 in the same period of 2023[164]. - Professional fees increased by 74.6% to $190,277 for the three-month period ended September 30, 2024, compared to $108,959 in the same period of 2023[164]. - Related party operating expenses rose by 81.8% to $405,771 for the three-month period ended September 30, 2024, up from $223,254 in the same period of 2023[164]. Research and Development - Research and development costs for the three months ended September 30, 2024, were $723,487, compared to $27,936 for the same period in 2023, reflecting a substantial increase in R&D investment[8]. - Research and development costs for the nine months ended September 30, 2024, amounted to $1,238,463, a substantial increase of 1,745.8% from $67,095 in the prior year[158]. - Grants received for research and development costs amounted to $1,756,852 for the nine months ended September 30, 2024, compared to $2,180,581 for the same period in 2023[78]. Equity and Liabilities - As of September 30, 2024, total liabilities amounted to $6,028,830, an increase from $5,665,177 as of December 31, 2023, representing an increase of approximately 6.4%[5]. - The total equity as of September 30, 2024, was $28,182,007, a decrease from $37,320,102 as of December 31, 2023, representing a decline of approximately 24.4%[6]. - The accumulated deficit rose significantly to $(31,318,226) in 2024, a 159.0% increase from $(12,092,927) in December 2023[177]. Cash Flow and Investments - Cash flows from operating activities resulted in a net cash used of $8,620,720 for the nine months ended September 30, 2024, compared to $5,086,987 for the same period in 2023[11]. - The company reported cash, cash equivalents, and restricted cash of $18,264,162 at the end of the period, down from $26,445,550 a year earlier[11]. - The company reported a net cash provided by investing activities of $20,045,260 for the nine months ended September 30, 2024, compared to $8,746,619 in 2023[182]. - The company had $16,679,428 in cash and $5,084,197 in short-term U.S. Treasury bills available for operations as of September 30, 2024[182]. Initial Public Offering (IPO) - The company completed an initial public offering (IPO) on September 20, 2023, raising gross proceeds of $19,999,992 from the sale of 1,666,666 Class A common shares at $12.00 per share[23]. - The increase in equity was primarily due to the IPO, partially offset by net losses from previous periods[180]. - The company issued 100,000 shares of Class A common shares in exchange for all non-controlling interests in PatentVest, making it a wholly owned subsidiary[152]. Segment Information - The company operates in two reportable segments: broker dealer and intellectual property service, and technology development, with distinct financial reporting for each[83]. - The Technology Development Segment reported a significant increase in revenue, with a total of $1,064,231 for 2024, up 192.4% from $363,907 in 2023[171]. Miscellaneous - The company has established a management subsidiary, MDB Management, to consolidate shared services for its U.S.-based operations[15]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from various reporting requirements[29]. - The company recognized no income tax expense for the nine months ended September 30, 2024, due to a full valuation allowance against net deferred tax assets[142].

Monrovia, CA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the pricing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share for a total of $15,000,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the “Offering”). I ...

Transformative Innovations in MASH Diagnostics According to PatentVest, there are several emerging areas for new patenting opportunities in the Biomarkers MASH and Artificial Intelligence Mark-up Language (AIML) spaces, with space for innovation and intellectual property protection. The great potential to create patent protection in the development of innovative diagnostic tools lies in: The "PatentVest Pulse" whitepaper is now available for download on the PatentVest website PatentVest Pulse in this link P ...

"We're thrilled to collaborate with Mayo Clinic to harness clinical and scientific expertise to develop therapeutics that could meaningfully improve patient lives across various conditions," said Christopher Marlett, CEO and Co-Founder of MDB. Founded in 1997, MDB Capital focuses on launching "Big Ideas" into valuable public companies with a better approach to public venture capital. This approach involves community-driven financings of pre-revenue, earlystage deep technology companies through early public ...